Retatrutide vs Tirzepatide: Which Triple-Agonist Wins

Retatrutide and tirzepatide are both Eli Lilly incretin-class compounds, separated by one critical mechanistic difference: retatrutide adds glucagon receptor agonism on top of the GLP-1 and GIP dual agonism that tirzepatide already provides. That third receptor changes everything about how the drugs compare.

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is FDA-approved, available, and has years of post-marketing real-world data. It produces about 20 to 22 percent body weight loss at 15mg in SURMOUNT-1 over 72 weeks, with a relatively gentle cardiovascular footprint and a well-characterised side effect profile dominated by transient GI effects.

Retatrutide is investigational, with Phase 3 TRIUMPH-1 topline results released May 21, 2026. At 12mg over 80 weeks, it produced 28.3 percent mean weight loss, climbing to 30.3 percent at week 104 in the BMI 35+ extension cohort. The glucagon arm drives additional fat mobilisation, hepatic fat clearance, and basal metabolic rate elevation, but also raises heart rate more than tirzepatide does and introduces a dose-dependent dysesthesia signal absent from tirzepatide trials.

For the obese clinical population, the choice is increasingly between approval status (tirzepatide today, retatrutide in late 2027 if no surprises) and magnitude of benefit (retatrutide wins). For enhanced athletes, the choice is more nuanced and depends on what the user is trying to accomplish.

Receptor pharmacology:

• Retatrutide: triple agonist, GLP-1 + GIP + glucagon receptors
• Tirzepatide: dual agonist, GLP-1 + GIP receptors
• The glucagon arm is the defining mechanistic addition in retatrutide. It drives hepatic glucose production, fatty acid oxidation, and basal metabolic rate elevation via FGF21 and uncoupling protein 1 activation (Conceição-Furber 2022).

Head-to-head weight loss (no direct trial exists):

• Retatrutide 12mg: 28.3 percent at week 80 (TRIUMPH-1, BMI 35+ subgroup 30.3 percent at week 104)
• Tirzepatide 15mg: 20.9 percent at week 72 (SURMOUNT-1)
• The roughly 7 to 8 percentage point gap favouring retatrutide is consistent across cross-trial comparisons, though trial duration and population differences make direct comparison imprecise.

Glycaemic effect (T2D Phase 2/3):

• Retatrutide 12mg: HbA1c reduction up to 2.02 percentage points over 36 weeks (Rosenstock 2023)
• Tirzepatide 15mg: HbA1c reduction approximately 1.9 to 2.1 percentage points (SURPASS-2 head-to-head vs semaglutide)
• Roughly equivalent in T2D contexts; retatrutide may have slight edge in non-diabetic obese.

Lipid effects:

• Retatrutide triglyceride drop up to 40.6 percent at 12mg (Phase 2)
• Tirzepatide triglyceride drop approximately 24.8 percent at 15mg
• Retatrutide ApoB reduction up to 24.2 percent, tirzepatide approximately 12 to 18 percent
• Glucagon arm enhances hepatic fatty acid oxidation, driving the additional lipid benefit.

Hepatic fat clearance:

• Retatrutide Phase 2a MASLD (Sanyal 2024): about 82 percent relative liver fat reduction at 8mg and 12mg, with about 90 percent achieving complete steatosis resolution
• Tirzepatide SYNERGY-NASH (Loomba 2024): MASH resolution approximately 62 percent at 15mg by liver biopsy
• Different endpoints (MASLD imaging vs MASH biopsy), but retatrutide appears clearly superior for hepatic fat reduction magnitude.

Body composition (lean mass loss):

• Tirzepatide SURMOUNT-1 DEXA substudy (Look 2025): about 25 percent of weight lost was lean mass (75/25 fat/lean ratio)
• Retatrutide T2D body composition substudy (Coskun 2025): lean mass loss "proportional to total weight loss, similar to other obesity treatments" (formal substudy on Phase 3 obesity cohort not yet published)
• Both expected to follow approximately 75/25 fat/lean ratio in obese trial populations. Lean athletes will likely see proportionally higher lean mass loss with either drug due to lower fat reserves.

Cardiovascular tolerability:

• Retatrutide HR rise: +5 to +10bpm at 8mg to 12mg, peaking around week 24 in Phase 2 (Jastreboff 2023). Network meta-analysis pooled +3.46bpm (Zhang 2026).
• Tirzepatide HR rise: +2 to +3bpm typically
• The glucagon arm drives the additional cardiac stimulation. Stimulant and stimulant-androgen stacking risk is meaningfully higher on retatrutide.

Side effect signal:

• Retatrutide: dysesthesia (burning, tingling skin) at 12.5 percent on 12mg vs 0.9 percent placebo in TRIUMPH-1. This is a new class signal absent from tirzepatide trials.
• AE-driven discontinuation: retatrutide 11.3 percent at 12mg, tirzepatide approximately 6 percent at 15mg

Approval status (May 2026):

• Retatrutide: investigational, not approved by any regulator. FDA submission expected late 2026, potential approval late 2027.
• Tirzepatide: FDA approved (Mounjaro for T2D 2022, Zepbound for obesity 2023), TGA approved in Australia, widely available globally.

Cost and access:

• Retatrutide: grey market sourcing only, approximately USD $80 to $200/month from research peptide vendors with no third-party purity validation
• Tirzepatide: brand-name USD $1,000+/month, insurance coverage variable, expanding compounding access in some jurisdictions due to shortage

Detection and legal risk:

• Retatrutide: investigational, no established detection assays in standard sport panels
• Tirzepatide: approved drug, not currently on WADA prohibited list, detectable in research-grade panels

Choose tirzepatide if:

• Legal, regulated access matters (FDA-approved, insurance possible, no grey-market sourcing risk)
• Cardiovascular tolerability is a priority (lower HR rise, no dysesthesia signal)
• You have any cardiac risk factors (CAD, arrhythmia history, untreated hypertension)
• Years of post-marketing safety data matter to you
• You are stacking with stimulants, T3, trenbolone, or clenbuterol where the additional HR load from retatrutide would be unsafe
• You need a predictable, well-characterised side effect profile

Choose retatrutide if:

• Maximum weight loss magnitude is the goal and you accept the additional risks
• You have significant hepatic steatosis or MASLD that needs aggressive intervention (the 82 percent liver fat reduction is unmatched)
• You have severe hypertriglyceridaemia (above 500 mg/dL) and need the strongest available triglyceride reduction
• Cost is a primary barrier and grey market sourcing is accessible to you
• You accept the dysesthesia and cardiac signal in exchange for the additional efficacy
• You have no cardiac risk factors and are not stacking other chronotropic compounds

It does not matter which you pick for:

• Routine T2D management at maximum doses (both reduce HbA1c by approximately 2 percentage points)
• Pure appetite suppression at lower doses (both effective, both well-tolerated)

Both require the same monitoring: Lipase at week 4, 12, 24; HbA1c and lipid panel at week 12 and 24; resting HR and BP from a wearable continuously.